SENSITIVITY TO CONVENTIONAL CHEMOTHERAPEUTIC DRUGS ACCORDING TO ARID1A DEFICIENCY OF OVARIAN CLEAR CELL CARCINOMA AND ENDOMETRIOID CARCINOMA CELLS

被引：0
|
作者：
Kuroda, T. [1 ,2 ]
Ogiwara, H. [1 ]
Takahashi, K. [1 ,2 ]
Sasaki, M. [1 ]
Yoshida, H. [3 ]
Kato, T. [4 ]
Okamoto, A. [2 ]
Kohno, T. [1 ]
机构：
[1] Natl Canc Ctr, Div Genome Biol, Res Inst, Tokyo, Japan
[2] Jikei Univ, Dept Obstet & Gynecol, Sch Med, Tokyo, Japan
[3] Natl Canc Ctr, Dept Pathol & Clin Labs, Tokyo, Japan
[4] Natl Canc Ctr, Dept Gynecol, Tokyo, Japan
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2018年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCS8-0330
引用
收藏
页码：180 / 180
页数：1
相关论文
共 50 条
  • [31] CCNE1 Amplification and Overexpression Characterizes Ovarian Clear Cell Carcinoma But Not Ovarian Endometrioid Carcinoma
    Ayhan, Ayse
    Ogawa, Hiroshi
    Bahadirli-Talbott, Asli
    Wu, Ren-Chin
    Sugimura, Haruhiko
    Wang, Tian-Li
    Shih, Ie-Ming
    LABORATORY INVESTIGATION, 2015, 95 : 273A - 274A
  • [32] Ovarian clear cell carcinoma with an immature teratoma component showing ARID1A deficiency and an identical PIK3CA mutation
    Kihara, Atsushi
    Iizuka, Toshihiko
    Endo, Shinichi
    Horie, Koji
    Kanda, Hiroaki
    Niki, Toshiro
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2021, 47 (09) : 3401 - 3407
  • [33] Suppression of ARID1A associated with decreased CD8 T cells improves cell survival of ovarian clear cell carcinoma
    Jung, Un Suk
    Min, Kyueng-Whan
    Kim, Dong-Hoon
    Kwon, Mi Jung
    Park, HoHyun
    Jang, Hyung Seok
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 32 (01) : 1 - 13
  • [34] Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma
    Yin, Min
    Lu, Chunli
    Zhou, Huimei
    Liu, Qian
    Yang, Jiaxin
    BMC WOMENS HEALTH, 2023, 23 (01)
  • [35] Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma
    Min Yin
    Chunli Lu
    Huimei Zhou
    Qian Liu
    Jiaxin Yang
    BMC Women's Health, 23
  • [36] ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component (vol 67, pg 866, 2014)
    Nishikimi, K.
    Kiyokawa, T.
    Tate, S.
    Iwamoto, M.
    Shozu, M.
    HISTOPATHOLOGY, 2016, 68 (04) : 621 - 621
  • [37] Synthetic lethal interaction between ARID1A mutation and BET bromodomain inhibition in ovarian clear cell carcinoma
    Berns, Katrien
    Caumanns, Joseph J.
    Hijmans, E. Marielle
    Gennissen, Annemiek
    Evers, Bastiaan
    Wisman, Bea A.
    Meersema, Gert Jan
    Lieftink, Cor
    Beijersbergen, Roderick L.
    Itamochi, Hiroaki
    van der Zee, Ate G.
    de Jong, Steven
    Bernards, Rene
    CANCER RESEARCH, 2017, 77
  • [38] SMARCA4 loss irrelevant for ARID1A mutated ovarian clear cell carcinoma: A case report
    Wagner, Samantha Kay
    Moon, Ashley S.
    Howitt, Brooke E.
    Renz, Malte
    GYNECOLOGIC ONCOLOGY REPORTS, 2023, 50
  • [39] Tubal origin of ovarian endometriosis and clear cell and endometrioid carcinoma
    Wang, Yiying
    Mang, Maggie
    Wang, Yue
    Wang, Lijie
    Klein, Robert
    Kong, Beihua
    Zheng, Wenxin
    AMERICAN JOURNAL OF CANCER RESEARCH, 2015, 5 (03): : 869 - 879
  • [40] Decreased ARID1A expression correlates with poor prognosis of clear cell renal cell carcinoma
    Park, Jeong Hwan
    Lee, Cheot
    Suh, Ja Hee
    Chae, Ji Yoen
    Kim, Hwal Woong
    Moon, Kyung Chul
    HUMAN PATHOLOGY, 2015, 46 (03) : 454 - 460
12345